PEG-MGF (Pegylated Mechano Growth Factor)
Also: Pegylated MGF, Pegylated Mechano Growth Factor, PEG MGF, MGF (pegylated), IGF-1Ec E-domain peptide (pegylated)
This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more
PEG-MGF is a synthetic, polyethylene-glycol-modified form of a peptide derived from the C-terminal E-domain of mechano growth factor (MGF), itself a splice variant of insulin-like growth factor 1 (IGF-1, sometimes designated IGF-1Ec). It is discussed in the research literature as a laboratory compound examined primarily in preclinical and in-vitro contexts within muscle and tissue biology. PEGylation is described in the chemistry literature as a strategy reported to slow degradation and extend the apparent circulating half-life relative to the native peptide. Evidence specific to the pegylated form is limited, largely preclinical, and requires careful interpretation due to study design and translation limitations.
Mechanism as described in the literature
Mechano growth factor (MGF) is a splice variant of insulin-like growth factor 1 that is reported in the literature to arise in mechanically loaded or stressed muscle tissue. The MGF-specific C-terminal E-domain peptide is described as acting, at least in part, through pathways characterized as distinct from classical signaling at the mature IGF-1 receptor, with in-vitro reports of effects on the proliferation and migration of muscle satellite (progenitor) cells. These mechanisms are characterized largely in cell-culture and animal models and are not fully resolved.
PEG-MGF denotes a version of this E-domain peptide chemically conjugated to polyethylene glycol (PEGylation). In peptide chemistry, PEGylation is a general technique reported to reduce enzymatic degradation and renal clearance, thereby extending the apparent half-life of an otherwise short-lived molecule. The functional consequences of this modification for MGF specifically remain incompletely characterized and are an open area of investigation.
Research areas
- Skeletal muscle satellite (progenitor) cell proliferation and migration as studied in vitro
- Muscle tissue repair and regeneration as investigated in animal models
- IGF-1 splice variant biology and E-domain peptide signaling
- Pharmacokinetic effects of PEGylation on peptide stability and apparent half-life
- Responses of cardiac and neural tissue to MGF/E-domain peptides in preclinical models
Documentation notes
References
Frequently asked questions
What is PEG-MGF?+
PEG-MGF is a research term for a pegylated form of the mechano growth factor (MGF) E-domain peptide, which is derived from a splice variant of the IGF-1 gene. It is discussed in the scientific literature as a laboratory compound, predominantly in preclinical and in-vitro studies. This entry is educational and does not address or direct human or animal use.
Is PEG-MGF the same as IGF-1?+
No. MGF is a splice variant arising from the IGF-1 gene and carries a distinct C-terminal E-domain peptide; PEG-MGF refers to a pegylated version of that E-domain peptide. The research literature describes overlapping but not identical biology, and the relationship between the two is an area of ongoing study.
What does the "PEG" refer to?+
PEG refers to polyethylene glycol, and "PEGylation" is the attachment of PEG to a peptide. In peptide chemistry this is described as a general technique reported to reduce degradation and extend a molecule's apparent half-life; its specific effects on MGF remain incompletely characterized.